Atypical Endometrial Hyperplasia Clinical Trial
Official title:
Operational Hysteroscopy Versus Traditional Surgery: Costs and Health Benefits
The study aims to evaluate the long-term efficacy and prognosis of hysteroscopic resection and coagulation of the base of endometrial polyps with focal atypia in fertile women.
The introduction of hysteroscopy in clinical practice changed significantly our knowledge of
uterine cavity, but did not stimulate the start of big studies with aim to evaluate the
feasibility of conservative treatments for better defined diseases as endometrial polyp. The
use of curettage(D&C) has led the gynecologists to consider diffuse atypical endometrial
hyperplasia and atypical polyp as the same disease. The treatment of these precancerous
lesions recommended by scientific societies is aggressive (hysterectomy). Surprisingly,
regarding hysterectomy we did not observe management modifications after the introduction of
endoscopic techniques, as happened in other surgical disciplines.
To evaluate costs and health benefits of operational hysteroscopy we started in our
Institute a study protocol in 1998. In a first trial we studied a conservative treatment of
postmenopausal woman with high anesthesiologic risk who had endometrial polyps with atypia
and no involvement of the base (Scrimin F. Am J Obstet Gynecol 2006;195:1328-30).
The good initial results and the request of conservative treatments by some women, desiring
pregnancies, encouraged us to start this preliminary trial to evaluate the long-term
efficacy and prognosis of hysteroscopic resection and coagulation of the base of endometrial
polyps with focal atypia in a little sample of fertile women. Other studies suggest
progestin treatment of well differentiated carcinoma in young women who desired to preserve
their fertility. There is no evidence of a correlation between the tendency to develop
endometrial polyps and the risk of endometrial carcinoma. The risk of malignant degeneration
of endometrial polyps is not well known, but seems to range between 0.5% and 6%. On this
background, we decided to study in the same population of fertile women and with a
quasi-randomised design the possible additional effect of levonorgestrel-releasing
intrauterine device (LNG-IUD).
Comparison: women assigned to odd numbers underwent polyp resection and endometrial
surveillance with insertion of levonorgestrel intrauterine system (IUD group), women
assigned to even numbers underwent polyp resection and endometrial surveillance without
insertion of levonorgestrel intrauterine system (no IUD or control group).
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02397083 -
Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT05647109 -
Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer
|
||
Completed |
NCT04491682 -
Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT00788671 -
Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer
|
Phase 2 | |
Completed |
NCT04385667 -
LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia
|
Phase 2/Phase 3 | |
Withdrawn |
NCT01943058 -
Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer
|
Phase 2 | |
Withdrawn |
NCT04683237 -
Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia
|
Phase 2/Phase 3 | |
Completed |
NCT00483327 -
Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
|
Phase 2 | |
Recruiting |
NCT05316493 -
Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia
|
Phase 2/Phase 3 | |
Completed |
NCT03241888 -
Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia
|
Phase 2/Phase 3 | |
Recruiting |
NCT05316935 -
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
|
Phase 2/Phase 3 | |
Recruiting |
NCT06390904 -
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients
|
Phase 2/Phase 3 | |
Recruiting |
NCT06379113 -
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
|
Phase 2/Phase 3 | |
Recruiting |
NCT05172999 -
Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia
|
Phase 2/Phase 3 | |
Recruiting |
NCT05675787 -
Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
|
Phase 2 | |
Active, not recruiting |
NCT03671811 -
Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy
|
Phase 2 | |
Terminated |
NCT04607252 -
Metformin Plus Megestrol Acetate as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia
|
Phase 2/Phase 3 | |
Recruiting |
NCT05051722 -
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
|
||
Active, not recruiting |
NCT00892866 -
CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells
|
N/A | |
Recruiting |
NCT03463252 -
Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC
|
Phase 2/Phase 3 |